Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 10;11:697967. doi: 10.3389/fonc.2021.697967

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zaryouh, De Pauw, Baysal, Pauwels, Peeters, Vermorken, Lardon and Wouters

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The cytotoxic effect of cetuximab plus MK2206 with a total treatment duration of 72h. Dose-response curves for the cetuximab sensitive HNSCC cell lines SC263-S (A) and SCC22b-S (B) show a synergistic effect. Regarding the acquired cetuximab resistant variants, dose-response curves indicate a synergistic and additive effect in SC263-R (C) and SCC22b-R (D), respectively. Survival curves were corrected for the cytotoxic effect of cetuximab alone. Cells were treated with fixed concentrations of cetuximab, which were chosen based on the outcome of previous monotherapy experiments. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.